甲状腺肿瘤诊疗新进展:从分子分型到靶向治疗的转化医学突破
New Advances in the Diagnosis and Treatment of Thyroid Tumors: Translational Medicine Breakthroughs from Molecular Typing to Targeted Therapy
DOI: 10.12677/acm.2025.1551667, PDF,    国家自然科学基金支持
作者: 乔 勇, 刘学礼*:阜阳师范大学附属阜南医院(阜南县人民医院)普外科,安徽 阜阳;李永生:安徽医科大学第一附属医院血管与甲状腺外科,安徽 合肥;陈洪让:安徽医科大学第一附属医院肝胆胰及移植外科二病区,安徽 合肥
关键词: 甲状腺肿瘤分子分型靶向治疗转化医学诊疗新进展Thyroid Tumors Molecular Typing Targeted Therapy Translational Medicine New Advances in Diagnosis and Treatment
摘要: 近年来,甲状腺肿瘤的研究取得了显著进展,尤其是在分子分型和靶向治疗方面。这一领域的重要性体现在甲状腺肿瘤的临床管理和预后评估中,传统的诊断和治疗方法逐渐无法满足个体化医疗的需求。当前,分子特征的识别为甲状腺肿瘤的分类和治疗提供了新的依据,但仍存在许多挑战,例如早期诊断的难度和靶向治疗的适应症界定。本文旨在综述甲状腺肿瘤的分子特征及其在诊疗中的应用,探讨最新的分子鉴定技术和靶向治疗策略,以期为临床医生提供一个全面的视角,帮助他们在甲状腺肿瘤的管理中作出更为精准的决策。
Abstract: In recent years, significant progress has been made in the study of thyroid tumors, particularly in molecular typing and targeted therapy. The importance of this field is reflected in the clinical management and prognostic evaluation of thyroid tumors, as traditional diagnostic and therapeutic approaches are increasingly inadequate to meet the demands of individualized medicine. Currently, the identification of molecular characteristics provides a novel basis for the classification and treatment of thyroid tumors; however, challenges persist, such as difficulties in early diagnosis and the precise delineation of indications for targeted therapies. This review aims to summarize the molecular features of thyroid tumors and their applications in diagnosis and treatment, while exploring the latest molecular profiling technologies and targeted therapeutic strategies. By integrating these advances, we seek to offer clinicians a comprehensive perspective to facilitate more precise clinical decision-making in thyroid tumor management.
文章引用:乔勇, 李永生, 陈洪让, 刘学礼. 甲状腺肿瘤诊疗新进展:从分子分型到靶向治疗的转化医学突破[J]. 临床医学进展, 2025, 15(5): 2681-2690. https://doi.org/10.12677/acm.2025.1551667

参考文献

[1] Boucai, L., Seshan, V., Williams, M., Knauf, J.A., Saqcena, M., Ghossein, R.A., et al. (2021) Characterization of Subtypes of BRAF-Mutant Papillary Thyroid Cancer Defined by Their Thyroid Differentiation Score. The Journal of Clinical Endocrinology & Metabolism, 107, 1030-1039. [Google Scholar] [CrossRef] [PubMed]
[2] Sabbagh, M.F., Janovitz, T., Dias-Santagata, D., Siegmund, S., Nardi, V., Wirth, L.J., et al. (2024) FGFR Alterations in Thyroid Carcinoma: A Novel Class of Primary Drivers with Significant Therapeutic Implications and Secondary Molecular Events Potentially Mediating Resistance in Thyroid Malignancy. Thyroid®, 34, 1137-1149. [Google Scholar] [CrossRef] [PubMed]
[3] Wang, Z., Han, Q., Hu, X., et al. (2025) Multi-Omics Clustering Analysis Carries out the Molecular-Specific Subtypes of Thyroid Carcinoma: Implicating for the Precise Treatment Strategies. Genes & Immunity, 26, 137-150. [Google Scholar] [CrossRef] [PubMed]
[4] Raue, F. and Frank-Raue, K. (2025) What Is New in Diagnostics and Management of Medullary Thyroid Carcinoma. In: Raue, F. and Frank-Raue, K. Eds., Medullary Thyroid Carcinoma, Springer Nature, 1-8. [Google Scholar] [CrossRef] [PubMed]
[5] Shobab, L., Al-Souri, D., Mathews-Kim, L., McCoy, M., Kuenstner, W., Hubbard, G.K., et al. (2024) PD-L1 Expression Varies in Thyroid Cancer Types and Is Associated with Decreased Progression Free Survival (PFS) in Patients with Anaplastic Thyroid Cancer. Cancers, 16, Article 3632. [Google Scholar] [CrossRef] [PubMed]
[6] Matrone, A., Citro, F., Gambale, C., Prete, A., Minaldi, E., Ciampi, R., et al. (2023) BRAF K601E Mutation in Oncocytic Carcinoma of the Thyroid: A Case Report and Literature Review. Journal of Clinical Medicine, 12, Article 6970. [Google Scholar] [CrossRef] [PubMed]
[7] Armos, R., Bojtor, B., Podani, J., Illyes, I., Balla, B., Putz, Z., et al. (2024) Descriptive Analysis of Common Fusion Mutations in Papillary Thyroid Carcinoma in Hungary. International Journal of Molecular Sciences, 25, Article 10787. [Google Scholar] [CrossRef] [PubMed]
[8] Boruah, M., Gaddam, P., Agarwal, S., Mir, R.A., Gupta, R., Sharma, M.C., et al. (2023) PD-L1 Expression in Rare and Aggressive Thyroid Cancers: A Preliminary Investigation for a Role of Immunotherapy. Journal of Cancer Research and Therapeutics, 19, 312-320. [Google Scholar] [CrossRef] [PubMed]
[9] Okafor, C., Hogan, J., Raygada, M., Thomas, B.J., Akshintala, S., Glod, J.W., et al. (2021) Update on Targeted Therapy in Medullary Thyroid Cancer. Frontiers in Endocrinology, 12, Article 708949. [Google Scholar] [CrossRef] [PubMed]
[10] Prabhash, K., Saldanha, E., Patil, V., et al. (2024) RET Alterations Differentiate Molecular Profile of Medullary Thyroid Cancer. JCO Precision Oncology, 8, e2300622. [Google Scholar] [CrossRef
[11] Yu, F., Zeng, G., Yang, L., Zhou, H. and Wang, Y. (2024) LAMB3: Central Role and Clinical Significance in Neoplastic and Non-Neoplastic Diseases. Biomedicine & Pharmacotherapy, 178, Article 117233. [Google Scholar] [CrossRef] [PubMed]
[12] Trocchianesi, S., Po, A., Citarella, A., Spinello, Z., Rughetti, A., Besharat, Z.M., et al. (2023) Molecular Mechanisms of the Tyrosine Kinase Inhibitor Pralsetinib Activity in in-vitro Models of Medullary Thyroid Carcinoma: Aberrant Activation of the HH-Gli Signaling Pathway in Acquired Resistance. Biomedicine & Pharmacotherapy, 164, Article 114995. [Google Scholar] [CrossRef] [PubMed]
[13] Cruz-Romero, S.D., González, S., Juez, J.Y., Becerra, D.S., Baldión, A.M., Hakim, J.A., et al. (2024) TIROSEC: Molecular, Clinical and Histopathological Profile of Papillary Thyroid Carcinoma in a Colombian Cohort. Advances in Therapy, 41, 792-805. [Google Scholar] [CrossRef] [PubMed]
[14] Chiba, T. (2024) Molecular Pathology of Thyroid Tumors: Essential Points to Comprehend Regarding the Latest WHO Classification. Biomedicines, 12, Article 712. [Google Scholar] [CrossRef] [PubMed]
[15] Hang, J., Chen, J., Kuo, P., Lai, H., Lee, T., Tai, S., et al. (2023) A Shift in Molecular Drivers of Papillary Thyroid Carcinoma Following the 2017 World Health Organization Classification: Characterization of 554 Consecutive Tumors with Emphasis on Braf-Negative Cases. Modern Pathology, 36, Article 100242. [Google Scholar] [CrossRef] [PubMed]
[16] Alexandraki, K.I., Papadimitriou, E., Spyroglou, A., Karapanagioti, A., Antonopoulou, I., Theohari, I., et al. (2024) Immunohistochemical Expression of Ephrin Receptors in Neuroendocrine Neoplasms: A Case-Series of Gastroenteropancreatic Neuroendocrine Neoplasms and a Systematic Review of the Literature. Endocrine, 87, 1323-1332. [Google Scholar] [CrossRef] [PubMed]
[17] Melone, V., Salvati, A., Palumbo, D., Giurato, G., Nassa, G., Rizzo, F., et al. (2022) Identification of Functional Pathways and Molecular Signatures in Neuroendocrine Neoplasms by Multi-Omics Analysis. Journal of Translational Medicine, 20, Article No. 306. [Google Scholar] [CrossRef] [PubMed]
[18] Alsugair, Z., Descotes, F., Lopez, J., Lasolle, H., Chazot, F.B., Lifante, J., et al. (2024) Clinically Aggressive Follicular Cell-Derived Thyroid Carcinoma: A Comprehensive Series with Histomolecular Characterization and Discovery of Novel Gene Fusions. Human Pathology, 153, Article 105674. [Google Scholar] [CrossRef] [PubMed]
[19] Rivera, J.P. and Hang, J. (2025) Next-Generation Immunohistochemistry in Thyroid Neoplasm: A Practical Review on the Applications in Diagnosis and Molecular Classification. Endocrine Pathology, 36, Article No. 8. [Google Scholar] [CrossRef] [PubMed]
[20] Gao, X., Hong, C., Xie, Y. and Zeng, X. (2023) Immunotherapy or Targeted Therapy: What Will Be the Future Treatment for Anaplastic Thyroid Carcinoma? Frontiers in Oncology, 13, Article 1103147. [Google Scholar] [CrossRef] [PubMed]
[21] Qin, L., Chen, C., Gui, Z. and Jiang, Y. (2024) IRX5’s Influence on Macrophage Polarization and Outcome in Papillary Thyroid Cancer. Frontiers in Oncology, 14, Article 1399484. [Google Scholar] [CrossRef] [PubMed]
[22] Mortensen, A.C.L., Imgenberg-Kreuz, J., Spiegelberg, D., Botling, J. and Nestor, M. (2023) Utilizing CD44v6 and V600EBRAF-Mutation for in vitro Targeted Combination Therapy of Thyroid Carcinomas. Heliyon, 9, e22594. [Google Scholar] [CrossRef] [PubMed]
[23] Zhang, L., Feng, Q., Wang, J., Tan, Z., Li, Q. and Ge, M. (2023) Molecular Basis and Targeted Therapy in Thyroid Cancer: Progress and Opportunities. Biochimica et Biophysica Acta (BBA)-Reviews on Cancer, 1878, Article 188928. [Google Scholar] [CrossRef] [PubMed]
[24] Currie, G. (2024) Molecular Theranostics: Principles, Challenges and Controversies. Journal of Medical Radiation Sciences, 72, 156-164. [Google Scholar] [CrossRef] [PubMed]
[25] Hamidi, S. and Maniakas, A. (2023) Recent Advances in Anaplastic Thyroid Cancer Management. Current Opinion in Endocrinology, Diabetes & Obesity, 30, 259-264. [Google Scholar] [CrossRef] [PubMed]
[26] Voinea, I., Petrova, E., Dumitru, N., Cocoloș, A., Ioachim, D., Goldstein, A.L., et al. (2024) Pathogenesis and Management Strategies in Radioiodine-Refractory Differentiated Thyroid Cancer: From Molecular Mechanisms toward Therapeutic Approaches: A Comprehensive Review. Journal of Clinical Medicine, 13, Article 7161. [Google Scholar] [CrossRef] [PubMed]